NASDAQ
05.06.25 | 21:59
3,175 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | H.C. Wainwright nimmt Beobachtung der PolyPid-Aktie mit Kaufempfehlung auf | 3 | Investing.com Deutsch | ||
| 30.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.05. | PolyPid bei Lytham Partners: Strategische Fortschritte und finanzielle Stabilität | 3 | Investing.com Deutsch | ||
| 21.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.05. | PolyPid GAAP EPS of -$0.70 beats by $0.12 | 1 | Seeking Alpha | ||
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 14.05. | PolyPid Ltd. Q1 Loss Beats Estimates | - | RTTNews | ||
| 14.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.05. | A Look Ahead: PolyPid's Earnings Forecast | 1 | Benzinga.com | ||
| 29.04. | PolyPid Ltd.: PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 | 2 | GlobeNewswire (USA) | ||
| 14.04. | H.C. Wainwright maintains Buy on PolyPid stock with $11 target | 2 | Investing.com | ||
| 11.03. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.02. | PolyPid Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 12.02. | PolyPid targets SHIELD II trial completion with top-line results in Q2 2025 | 1 | Seeking Alpha | ||
| 12.02. | PolyPid GAAP EPS of -$1.13 misses by $0.31 | 2 | Seeking Alpha | ||
| 12.02. | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 29.01. | PolyPid Ltd.: PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025 | 3 | GlobeNewswire (USA) | ||
| 21.01. | PolyPid files for secondary offering | 1 | Seeking Alpha | ||
| 17.01. | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 26.12.24 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.12.24 | PolyPid Ltd.: PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX100 to 800 Patients with a Concurrent Private Placement of up to $41 Million | 155 | GlobeNewswire (Europe) | • 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; • Upon Potential Positive Phase 3 Data the Company Expects to Submit a... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,45 | +0,21 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen | |
| EVOTEC | 7,056 | +0,89 % | DAX nach Feiertag wieder bei 24.000 - Douglas, Evotec, Fresenius, Merck, Renk und SAP im Check | An Christi Himmelfahrt hat es am deutschen Aktienmarkt bei dünnen Umsätzen etwas an Boden verloren. Die Verluste macht der DAX aber am letzten Handelstag im Mai schon wieder gut, wobei die Zollpolitik... ► Artikel lesen | |
| CUREVAC | 3,836 | -1,74 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
| AMGEN | 254,90 | +1,53 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,548 | +10,48 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,449 | -2,60 % | Breaking News: NurExone gibt die Planung und Details der klinischen Humanstudie mit ExoPTEN bekannt! | ||
| IBIO | 0,910 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results | SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 14,730 | +2,40 % | Jim Cramer on Arrowhead Pharmaceuticals (ARWR): "It Doesn't Make Any Money" | ||
| COHERUS ONCOLOGY | 0,700 | -0,40 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,978 | +3,33 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
| MEREO BIOPHARMA | 2,290 | +6,02 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights | Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 16,170 | -3,17 % | Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases | STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating... ► Artikel lesen | |
| BENITEC BIOPHARMA | 15,100 | -0,46 % | Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update | -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular... ► Artikel lesen | |
| CYBIN | 7,900 | +1,94 % | CYBIN INC. - 6-K, Report of foreign issuer |
POLYPID LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,175 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.